The stock of Inovio Pharmaceuticals Inc (NASDAQ: INO) has increased by 3.48 when compared to last closing price of 4.02.Despite this, the company has seen a loss of -3.70% in its stock price over the last five trading days. prnewswire.com reported 2024-12-03 that Data from a retrospective trial evaluating the longer-term benefit of INO-3107 to patients with Recurrent Respiratory Papillomatosis (RRP) involved in a Phase 1/2 trial showed the number of patients who met the criteria for a Complete Response (CR) increased to 50% by the end of year 2 and to 54% in year 3, compared to 28% by the end of the initial 52-week trial 95% of patients in the retrospective trial (RRP-002) maintained or enhanced their original Overall Response Rate (ORR) reported in the Phase 1/2 trial (RRP-001) by the end of year 2; 86% of patients maintained or enhanced ORR into year 3 New durability data will help inform re-dosing strategy focused on long-term elimination or reduction in the need for surgery to treat RRP disease INOVIO plans to present data at future scientific conferences and submit for publication in peer-reviewed journals PLYMOUTH MEETING, Pa., Dec. 3, 2024 /PRNewswire/ — INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced data from a retrospective trial showing that the number of RRP patients meeting the criteria for a Complete Response increased to 50% by the end of the second year following initial treatment with INO-3107 in a previously reported Phase 1/2 52-week trial where the Complete Response rate was 28%.
Is It Worth Investing in Inovio Pharmaceuticals Inc (NASDAQ: INO) Right Now?
Additionally, the 36-month beta value for INO is 0.72. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for INO is 25.80M and currently, short sellers hold a 14.55% ratio of that float. The average trading volume of INO on December 06, 2024 was 347.50K shares.
INO’s Market Performance
INO stock saw a decrease of -3.70% in the past week, with a monthly decline of -26.63% and a quarterly a decrease of -35.10%. The volatility ratio for the week is 5.48%, and the volatility levels for the last 30 days are 6.08% for Inovio Pharmaceuticals Inc (INO). The simple moving average for the past 20 days is -5.16% for INO’s stock, with a -51.02% simple moving average for the past 200 days.
Analysts’ Opinion of INO
Many brokerage firms have already submitted their reports for INO stocks, with Stephens repeating the rating for INO by listing it as a “Overweight.” The predicted price for INO in the upcoming period, according to Stephens is $20 based on the research report published on May 14, 2024 of the current year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see INO reach a price target of $4. The rating they have provided for INO stocks is “Outperform” according to the report published on January 25th, 2024.
INO Trading at -18.77% from the 50-Day Moving Average
After a stumble in the market that brought INO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.79% of loss for the given period.
Volatility was left at 6.08%, however, over the last 30 days, the volatility rate increased by 5.48%, as shares sank -23.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.41% lower at present.
During the last 5 trading sessions, INO fell by -2.31%, which changed the moving average for the period of 200-days by -44.91% in comparison to the 20-day moving average, which settled at $4.39. In addition, Inovio Pharmaceuticals Inc saw -32.03% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for INO
Current profitability levels for the company are sitting at:
- -587.1 for the present operating margin
- -7.67 for the gross margin
The net margin for Inovio Pharmaceuticals Inc stands at -124147.37. The total capital return value is set at 0.01. Equity return is now at value -106.64, with -75.21 for asset returns.
Based on Inovio Pharmaceuticals Inc (INO), the company’s capital structure generated 0.99 points at debt to capital in total, while cash flow to debt ratio is standing at -6.78. The debt to equity ratio resting at 169.23. The interest coverage ratio of the stock is -259.53.
Currently, EBITDA for the company is -130.39 million with net debt to EBITDA at 84.11. When we switch over and look at the enterprise to sales, we see a ratio of -44896.45. The receivables turnover for the company is 0.11for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.88.
Conclusion
In conclusion, Inovio Pharmaceuticals Inc (INO) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
